An Indian Scenario: Emerging Advances in Nanotechnology as Drug Delivery System in Rheumatoid Arthritis

Abstract

There are several significant assays including bioavailability, Toxicity, high clearance, and further current therapies require higher and frequent dosing to gain desired therapeutic effects for Rheumatoid arthritis (RA). Nanoparticles have been widely investigated for rheumatoid arthritis (RA). Though, higher doses of Nanocarriers also increase the incidence of dreadful adverse effects. Wherever, nanocarrier properties are most populated by the use of different approaches like targeting ligands, to change the physicochemical properties including higher encapsulation, better penetrating ability in cells etc. The main advantage of the nanocarrier that they provide longer circulation which enhances drug localization at the inflamed site and selective targeting to enhance the therapeutic index of anti-arthritic drugs. However, the optimal properties of nanocarrier also depend on the route of administration and size of particles, thus larger size show more retention upon local injection and smaller sized ones are more optimal for passive targeting. The present article discusses the emergence of nano-carriers for anti-rheumatic drugs, which delivers drug molecule to the inflamed site by topical, intra-articular (i.a) and intra-venous (i.v) administration to take advantage of therapeutic efficacy by passive and active drug delivery. Advancements have been made extensively but still better investigations are needed to achieve the risk-benefit ratio for the development of safe, stable and effective targeting nanocarriers for the e treatment of rheumatoid arthritis (RA).